Back to Search Start Over

Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomized controlled trial.

Authors :
Saab, Karim
Gada, Umang
Culakova, Eva
Burnette, Brian
Jorgensen, Carla
Shah, Dhaval
Morrow, Gary
Mustian, Karen
Sohn, Michael B
Edwards, Robert R
Freeman, Roy
Langford, Dale J
McDermott, Michael P
Gewandter, Jennifer S
Source :
Pain Medicine; Jan2025, Vol. 26 Issue 1, p22-29, 8p
Publication Year :
2025

Abstract

Objective To explore the clinical relevance and assay sensitivity of using personalized outcomes using data from a randomized clinical trial (RCT) in people with chemotherapy-induced peripheral neuropathy (CIPN). Design This study is a secondary analysis that leveraged data from a RCT of transcutaneous electrical stimulation for CIPN to test whether personalized outcomes could minimize potential floor effects and increase the assay sensitivity of pain clinical trials (ie, ability to detect a true treatment effect). Setting Participants were recruited for a RCT from community oncology clinics in the United States. Participants Adults with CIPN (N  = 72) who reported on average ≥4 intensity (measured via a 7-day baseline diary) for at least 1 of the following pain qualities: hot/burning pain, sharp/shooting pain, and/or cramping. Methods Personalized outcomes were defined based on participants' unique presentation of pain qualities at baseline, measured via 0-10 numeric rating scales (NRS), or ranking of the distress caused by the pain qualities. Analysis of covariance models estimated the treatment effect as measured by personalized and non-personalized outcomes. Results The adjusted mean difference between groups was higher using personalized outcomes (ie, 1.21-1.25 NRS points) compared to a non-personalized outcome (ie, 0.97 NRS points), although the standardized effect sizes were similar between outcomes (0.49-0.54). Conclusions These results suggest that personalized pain quality outcomes could minimize floor effects, while providing similar assay sensitivity to non-personalized pain quality outcomes. Personalized outcomes better reflect an individual's unique experience, inherently providing more clinically relevant estimates of treatment effects. Personalized outcomes may be advantageous, particularly for clinical trials in populations with high inter-individual variability in pain qualities. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15262375
Volume :
26
Issue :
1
Database :
Complementary Index
Journal :
Pain Medicine
Publication Type :
Academic Journal
Accession number :
182194975
Full Text :
https://doi.org/10.1093/pm/pnae095